Growth in all three of its business segments powered nuclear medicine firm MDS Nordion of Ottawa to higher revenue levels in the company's third quarter of its 2010 fiscal year (end-July 31).
Revenue increased 4% to $53 million (U.S.), compared with $49 million in the third quarter of fiscal 2009. The company's loss from continuing operations was $18 million, compared with income from continuing operations of $9 million in the third quarter of fiscal 2009.
MDS also recorded an operating loss of $4 million from discontinued operations in the third quarter of fiscal 2010, compared with an operating loss of $56 million in the third quarter of fiscal 2009.
Related Reading
MDS extends cobalt-60 supply deal, August 13, 2010
Lantheus, MDS Nordion sign Mo-99 deal, July 8, 2010
MDS Nordion, Guerbet to develop PET agents, June 24, 2010
MDS posts Q2 loss, June 15, 2010
MDS changes name to Nordion, March 16, 2010
Copyright © 2010 AuntMinnie.com
